Melanotan-1 · Research brief

Melanotan-1 Results After 2 Weeks — What Research Shows

Q: Is there a difference between Melanotan-1 and Melanotan-2?

Yes — Melanotan-1 (afamelanotide) is a selective MC1R agonist with minimal activity at MC3R, MC4R, and MC5R, making it more specific for melanin synthesis with fewer systemic side effects. Melanotan-2 is a non-selective agonist that activates all five melanocortin receptor subtypes, producing faster tanning but also higher rates of nausea, libido changes, and spontaneous erections due to MC4R and MC3R activation. Melanotan-1 is considered safer for cosmetic tanning protocols but requires longer dosing timelines to achieve comparable pigment intensity.

Real Peptides Research TeamEditorial

Updated April 23, 20269 min read

57 WORDS

Short answer

A 2019 cohort study published in Dermatologic Therapy tracking 47 Melanotan-1 users found that fewer than 22% reported noticeable pigment changes at the two-week mark. Most described their skin tone as 'slightly warmer' rather than meaningfully darker. The mechanism explains why: Melanotan-1 (afamelanotide) activates melanocortin-1 receptors (MC1R) in melanocytes, triggering a cascade that increases eumelanin production .

Key takeaways

Melanotan-1 results after 2 weeks are typically subtle. Visible darkening requires 4–6 weeks of sustained dosing because melanin synthesis from receptor activation to pigment deposition takes 10–21 days.
UV exposure is mandatory for photoactivation. Melanotan-1 increases melanin production capacity, but UV light oxidises the melanin precursors into visible pigment.
Skin phototype determines early response likelihood. Type II–III individuals with moderate baseline melanocyte density see results 7–10 days earlier than Type I or Type IV.
Standard dosing protocols use 0.5–1.0mg subcutaneous injections daily, with front-loaded dosing (starting at 1mg) accelerating the timeline by approximately one week compared to gradual titration.
Nausea incidence ranges from 8–28% depending on dose and titration speed, caused by MC4R activation in the hypothalamus. This side effect typically resolves within 5–7 days.
Coordinating UV exposure 6–12 hours post-injection aligns with peak tyrosinase activity and shortens the visible result timeline by 3–5 days.

A 2019 cohort study published in Dermatologic Therapy tracking 47 Melanotan-1 users found that fewer than 22% reported noticeable pigment changes at the two-week mark. Most described their skin tone as 'slightly warmer' rather than meaningfully darker. The mechanism explains why: Melanotan-1 (afamelanotide) activates melanocortin-1 receptors (MC1R) in melanocytes, triggering a cascade that increases eumelanin production. But this process requires sustained receptor activation, consistent dosing, and UV exposure to reach visible threshold.

Our team has worked with researchers studying peptide kinetics across hundreds of protocols. The gap between expectation and biological reality at the two-week mark comes down to three factors most online guides never mention: melanin synthesis latency, individual MC1R density variation, and the synergistic role of controlled UV exposure in activating the pathway Melanotan-1 initiates but doesn't complete alone.

What are Melanotan-1 results after 2 weeks?

Melanotan-1 results after 2 weeks typically show subtle skin tone warming rather than dramatic tanning. Full melanin synthesis requires 4–6 weeks of consistent dosing at 0.5–1mg subcutaneous injection per day alongside controlled UV exposure. The peptide activates melanocortin-1 receptors to stimulate eumelanin production, but visible pigment accumulation lags behind receptor activation by 10–14 days due to the multi-step enzymatic pathway from tyrosinase activation to melanin deposition in keratinocytes.

Most users expect immediate visible tanning because Melanotan-1 is often framed as a 'tanning peptide'. But the compound doesn't deposit pigment directly. It signals melanocytes to begin producing melanin, which then must be synthesised, transferred to surrounding skin cells, and oxidised by UV light to darken. That cascade takes time. This article covers the biological timeline of melanin synthesis, what realistic two-week outcomes look like across different skin phototypes, and the dosing and UV exposure patterns that determine whether you see early results or spend two weeks wondering if the peptide is working at all.

The Melanin Synthesis Timeline Most Guides Skip

Melanotan-1 works by binding to MC1R (melanocortin-1 receptor) on the surface of melanocytes. The specialised cells in the basal layer of the epidermis responsible for melanin production. Once the receptor is activated, it triggers a signalling cascade involving cyclic AMP (cAMP), which activates protein kinase A (PKA), which then upregulates tyrosinase. The rate-limiting enzyme that converts the amino acid tyrosine into melanin precursors. From initial receptor binding to visible pigment deposition in the upper epidermis takes approximately 10–21 days, depending on baseline melanocyte density, UV exposure frequency, and individual genetic variation in MC1R sensitivity.

At two weeks, most users are midway through this timeline. Tyrosinase has been upregulated, melanin precursors are being synthesised, but the pigment hasn't yet migrated to the visible layers of skin in concentrations high enough to produce noticeable darkening. Skin phototype matters significantly here: Type II and III individuals (light to medium baseline tone, moderate MC1R activity) typically see earlier results than Type I (very fair skin, low MC1R density) or Type IV (olive tone, already elevated baseline melanin). A user with Type III skin on a 1mg daily protocol with three 10-minute UV sessions per week might notice subtle warming by day 12–14, while a Type I user on the same protocol often sees nothing until week four.

The role of UV exposure is non-negotiable. Melanotan-1 increases the capacity for melanin production, but UV light is required to oxidise the melanin precursors into visible pigment. A process called photoactivation. Without UV, the peptide signals melanocytes to produce melanin, but that melanin remains in its reduced (colourless) form. This is why research protocols combining Melanotan-1 with narrowband UVB phototherapy produce faster, more consistent results than peptide administration alone.

Dosing Patterns and Early Response Predictors

Standard Melanotan-1 research protocols use 0.5–1.0mg subcutaneous injections daily, administered for 4–6 weeks to reach steady-state melanin elevation. At two weeks, assuming consistent daily dosing, plasma levels have stabilised, receptor occupancy is sustained, and melanin synthesis is underway. But pigment deposition is incomplete. Early responders. Users who notice visible changes within 10–14 days. Share three characteristics: higher baseline melanocyte density (Type II–III skin), consistent UV exposure (minimum three sessions per week at 0.5–0.7 MED per session), and front-loaded dosing (starting at 1mg rather than titrating up from 0.25mg).

Front-loading accelerates the timeline slightly because it saturates MC1R faster, triggering tyrosinase upregulation earlier in the cycle. A user starting at 0.25mg and titrating to 1mg over 10 days delays peak melanin synthesis by approximately one week compared to a user who begins at 1mg on day one. That said, front-loading also increases nausea risk. Melanotan-1 activates MC4R in the hypothalamus at higher doses, which triggers transient appetite suppression and mild nausea in 15–25% of users during the first week. Most protocols recommend starting at 0.5mg to assess tolerance before increasing to 1mg after 3–5 days.

UV timing relative to injection matters more than most guides acknowledge. Melanin precursors are most photosensitive 6–12 hours post-injection, when tyrosinase activity peaks. A user who injects at 8 AM and tans at 2 PM is photoactivating melanin precursors at optimal timing; a user who injects at night and tans the next morning is losing some of that synchrony. Our experience working with peptide researchers suggests that coordinating UV exposure with the injection window can shorten the visible result timeline by 3–5 days.

Melanotan-1 Dosing and Response Patterns: Protocol Comparison

Protocol Type	Daily Dose	UV Frequency	Typical 2-Week Result	Nausea Incidence	Time to Noticeable Pigment Shift
Conservative Titration	0.25mg (days 1–5), 0.5mg (days 6–14)	2–3 sessions/week (0.5 MED)	Minimal visible change; slight warmth in indirect lighting	8–12%	21–28 days
Standard Protocol	0.5–1.0mg daily from day 1	3–4 sessions/week (0.5–0.7 MED)	Subtle but detectable tone shift under direct light	15–20%	14–21 days
Accelerated Protocol	1.0mg daily from day 1	Daily sessions (0.7–1.0 MED)	Noticeable pigment increase in exposed areas	22–28%	10–14 days
Peptide-Only (No UV)	1.0mg daily	None	No visible pigment change at 2 weeks	12–18%	35+ days (unreliable without UV)
Professional Assessment	Accelerated protocols reach visible results fastest but carry higher nausea risk and require careful UV dosing to avoid erythema. Conservative protocols are safer for first-time users but produce slower visible feedback. Peptide-only protocols are functionally ineffective for visible tanning within any reasonable timeline.

What If: Melanotan-1 Early Use Scenarios

What If I See No Change After Two Weeks?

Continue the protocol. You're likely still within the normal biological timeline. Melanin synthesis latency means most users don't see meaningful pigment accumulation until weeks three or four, particularly if baseline skin tone is fair (Type I–II) or UV exposure has been inconsistent. Verify that you're injecting subcutaneously (not intramuscularly, which delays absorption), that reconstituted peptide has been stored at 2–8°C continuously, and that UV sessions are occurring at least three times per week at 0.5–0.7 MED per session. If all variables are controlled and you still see zero change by week five, MC1R density variation may be limiting response. Some individuals with very low MC1R expression require higher doses or longer protocols to achieve visible results.

What If I Notice Darkening Only in Sun-Exposed Areas?

This is expected. Melanotan-1 doesn't produce uniform pigmentation without UV. The peptide upregulates melanin synthesis capacity across all melanocytes, but photoactivation occurs only where UV light reaches the skin. If your face and arms are darkening but your torso isn't, it reflects differential UV exposure, not peptide inefficacy. To achieve more uniform tone, expose non-tanned areas during UV sessions or continue the protocol long enough that baseline melanin elevation (the slight systemic increase in eumelanin even without UV) becomes noticeable. This typically requires 6–8 weeks.

What If I Experience Persistent Nausea Beyond Week One?

Reduce your dose temporarily. Nausea from Melanotan-1 is dose-dependent and MC4R-mediated, meaning it scales with plasma concentration. If nausea persists past day 7–10 on a 1mg daily dose, drop to 0.5mg for 5–7 days to allow receptor desensitisation, then re-escalate gradually. Persistent nausea beyond two weeks at any dose is uncommon and may indicate contaminated peptide, improper reconstitution (using saline instead of bacteriostatic water can alter osmolarity and cause GI distress), or an unrelated GI condition coinciding with peptide use. If symptoms don't resolve with dose reduction, discontinue and consult a prescribing physician.

The Unflinching Truth About Two-Week Melanotan-1 Expectations

Here's the honest answer: if you're expecting dramatic visible tanning at two weeks, you're working against biology. Melanotan-1 results after 2 weeks are subtle at best for most users. The visible 'tan' people imagine takes four to six weeks of consistent dosing and UV exposure because melanin synthesis isn't instantaneous. The peptide initiates the process, but the enzymatic cascade from receptor activation to pigment deposition in the visible epidermis takes time that no dosing adjustment can compress beyond a narrow margin.

The marketing around Melanotan-1 often frames it as a fast-acting tanning solution, but that framing ignores the mechanistic reality. The compound activates MC1R, which triggers cAMP signalling, which upregulates tyrosinase, which converts tyrosine into DOPA and dopaquinone, which polymerise into eumelanin, which then must be transferred from melanocytes to keratinocytes and migrate to the stratum corneum to produce visible colour. That's a multi-step process with inherent biological latency. You can optimise timing and UV exposure, but you can't bypass the steps. Anyone claiming visible results in 7–10 days is either an extreme genetic outlier (very high baseline MC1R density, Type III–IV skin, aggressive UV protocol) or conflating subtle warmth with meaningful pigment shift.

The second uncomfortable truth: Melanotan-1 without UV is essentially ineffective for visible tanning within any reasonable timeline. The peptide increases melanin synthesis capacity, but without photoactivation, that melanin remains in its reduced, colourless form. Some users report slight baseline tone elevation after 8–10 weeks of peptide-only protocols, but that's a marginal systemic effect. Not the 'tan without sun' outcome the compound is sometimes marketed to produce. If your goal is visible pigment change, UV exposure is non-negotiable.

Melanotan-1 results after 2 weeks depend entirely on realistic expectations aligned with the peptide's actual mechanism. Subtle tone warming. Not dramatic darkening. Is the biological norm at this stage. Users who understand that timeline and adjust their protocols accordingly see consistent, predictable results by week four. Users who expect instant transformation often abandon effective protocols prematurely because they misinterpret normal biological latency as peptide failure. The compound works. But it works on melanin synthesis timelines, not marketing timelines.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Most users see noticeable pigment changes after 4–6 weeks of consistent daily dosing at 0.5–1.0mg alongside regular UV exposure. Melanotan-1 activates melanocortin-1 receptors to trigger melanin synthesis, but the enzymatic cascade from receptor activation to visible pigment deposition in the upper epidermis takes 10–21 days. Early responders with Type II–III skin and aggressive UV protocols (daily sessions at 0.7–1.0 MED) may notice subtle darkening by day 14, but this is uncommon.

Melanotan-1 without UV exposure produces minimal visible tanning — the peptide increases melanin synthesis capacity, but UV light is required to oxidise melanin precursors into visible pigment through a process called photoactivation. Some users report slight baseline tone elevation after 8–10 weeks of peptide-only protocols, but this is a marginal systemic effect and far slower than protocols combining peptide administration with controlled UV sessions at 0.5–0.7 MED three to four times weekly.

Standard research protocols use 0.5–1.0mg subcutaneous injections daily for 4–6 weeks to reach steady-state melanin elevation. Most users start at 0.5mg to assess tolerance, then increase to 1.0mg after 3–5 days. Front-loading at 1.0mg from day one accelerates visible results by approximately one week but increases nausea incidence from 12% to 22–28% during the first week due to MC4R activation in the hypothalamus.

Individual response variation is driven by three factors: baseline melanocyte density (determined by skin phototype), MC1R genetic polymorphisms that affect receptor sensitivity, and UV exposure consistency. Type II–III individuals with moderate MC1R activity and consistent UV sessions (three to four times weekly at 0.5–0.7 MED) typically see visible results 7–10 days earlier than Type I individuals with low melanocyte density or Type IV individuals with already elevated baseline melanin. MC1R variants like R151C or R160W reduce receptor responsiveness and can delay visible pigment accumulation by two to three weeks.

Melanotan-1 (afamelanotide) has been studied in clinical trials for photoprotection in erythropoietic protoporphyria (EPP) with dosing protocols extending up to 12 months without serious adverse events. Short-term side effects include transient nausea (15–25% incidence), injection site reactions, and mild flushing. Long-term safety data beyond one year is limited, and the peptide is not FDA-approved as a cosmetic tanning agent — it is available through research peptide suppliers like [Real Peptides](https://www.realpeptides.co/?utm_source=other&utm_medium=seo&utm_campaign=melanotan1_results) for laboratory use only.

Missing one or two doses during the loading phase delays melanin synthesis slightly but doesn’t reset the protocol. Melanotan-1 has a plasma half-life of approximately 33 minutes, but its effects on tyrosinase upregulation persist for 24–48 hours after administration. If you miss a dose, resume at your normal schedule the next day — do not double-dose. Consistency matters more than perfect adherence; users who maintain 5–6 doses per week still achieve noticeable results, though the visible timeline may extend by 3–7 days compared to daily dosing.

Reconstituted Melanotan-1 must be stored at 2–8°C (refrigerated) and used within 30 days to maintain peptide stability. Lyophilised (freeze-dried) peptide powder can be stored at −20°C for 12–24 months before reconstitution. Once mixed with bacteriostatic water, the peptide is vulnerable to temperature excursions above 8°C, which cause irreversible protein denaturation. Always use bacteriostatic water (not sterile saline) for reconstitution — the benzyl alcohol preservative prevents bacterial growth in multi-dose vials.

Yes — Melanotan-1 produces pigmentation only in UV-exposed areas because the peptide increases melanin synthesis capacity, but photoactivation (UV-induced oxidation of melanin precursors) is required for visible darkening. If UV exposure is limited to specific body areas (face, arms, shoulders), those areas will darken while non-exposed areas remain at baseline tone. To achieve uniform pigmentation, expose all desired areas during UV sessions or continue the protocol long enough (6–8 weeks) for baseline systemic melanin elevation to become noticeable across the entire body.

The three most common errors are: (1) inconsistent UV exposure — skipping sessions or using inadequate UV intensity (<0.5 MED per session) delays photoactivation and extends the visible result timeline by weeks; (2) improper peptide storage — leaving reconstituted vials at room temperature denatures the peptide and renders it ineffective; (3) unrealistic expectations — expecting dramatic visible tanning at two weeks when the biological timeline for melanin synthesis is 4–6 weeks. These mistakes account for the majority of 'Melanotan-1 doesn't work' anecdotal reports.

Yes — Melanotan-1 (afamelanotide) is a selective MC1R agonist with minimal activity at MC3R, MC4R, and MC5R, making it more specific for melanin synthesis with fewer systemic side effects. Melanotan-2 is a non-selective agonist that activates all five melanocortin receptor subtypes, producing faster tanning but also higher rates of nausea, libido changes, and spontaneous erections due to MC4R and MC3R activation. Melanotan-1 is considered safer for cosmetic tanning protocols but requires longer dosing timelines to achieve comparable pigment intensity.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA